Marks Group Wealth Management Inc Sells 686 Shares of AstraZeneca PLC (NASDAQ:AZN)

Marks Group Wealth Management Inc lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,672 shares of the company’s stock after selling 686 shares during the quarter. Marks Group Wealth Management Inc’s holdings in AstraZeneca were worth $3,402,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AZN. Martin Investment Management LLC raised its stake in shares of AstraZeneca by 2.8% in the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after acquiring an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC raised its position in AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares during the last quarter. Creative Planning boosted its stake in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after purchasing an additional 16,692 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of AstraZeneca by 8.6% during the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after purchasing an additional 121,876 shares during the last quarter. Finally, Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at $269,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AZN shares. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $66.27 on Wednesday. The firm has a fifty day moving average of $78.87 and a two-hundred day moving average of $78.77. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock has a market capitalization of $205.48 billion, a price-to-earnings ratio of 32.01, a PEG ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.